Caroline Peachey

apanese company Otsuka Pharmaceutical will pay $65 million is to commercialise Ionis’ hereditary angioedema drug candidate in Europe.

A coordinated workplan, which runs to 2028 will help European regulators embrace opportunities for artificial intelligence in regulation.

Contract development and manufacturing organisation, Piramal Pharma Solutions, has expanded its ADC manufacturing facility in Scotland.

Subin Baral, EY Global Deals Leader, Life Sciences discusses biopharma dealmaking in 2023 and the investment outlook for 2024.

EPR’s Caroline Peachey explores some key considerations and strategies for pharma companies considering outsourcing regulatory activities.

Henry Levy, President, Life Sciences at Clarivate discusses how AI, and particularly GenAI, is transforming the pharma industry.

Two European Pharmacopoeia monographs allow the use of recombinant factor C (rFC) to test for bacterial endotoxins in pharmaceutical waters.

Contract development and manufacturing organisation Delpharm has acquired a European pharmaceutical manufacturing in Meppel from Astellas.

In this podcast, Dr Neena Haider and Dr Arun Upadhyay, discuss the development of modifier gene therapy for ocular diseases.

Giovanni Nisato from the Pistoia Alliance discusses data integrity and implementation of FAIR data principles in the pharmaceutical industry.